The trajectory of Sildenafil presents a intricate picture for investors. While the initial launch generated significant returns, the end of its intellectual property protection opened the door to off-brand alternatives, dramatically eroding sales. This poses a specific dilemma for firms banking on similar blockbuster products, suggesting that a bli

The story of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, generating billions in revenue , its patent expiration created a wave of knock-off medications, significantly eroding its dominance. While certain businesses may try to capitalize on similar conditions , the present landscape de